These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27432118)

  • 41. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
    Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
    World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer.
    Verhoeff SR; van Erning FN; Lemmens VE; de Wilt JH; Pruijt JF
    Int J Cancer; 2016 Jul; 139(1):187-93. PubMed ID: 26914273
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SOX9 expression predicts relapse of stage II colon cancer patients.
    Marcker Espersen ML; Linnemann D; Christensen IJ; Alamili M; Troelsen JT; Høgdall E
    Hum Pathol; 2016 Jun; 52():38-46. PubMed ID: 26980019
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of MVD, LVD and vascular invasion in lymph node-negative colon cancer.
    Sundov Z; Tomic S; Alfirevic S; Sundov A; Capkun V; Nincevic Z; Nincevic J; Kunac N; Kontic M; Poljak N; Druzijanic N
    Hepatogastroenterology; 2013 May; 60(123):432-8. PubMed ID: 23321007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer.
    Casadaban L; Rauscher G; Aklilu M; Villenes D; Freels S; Maker AV
    Cancer; 2016 Nov; 122(21):3277-3287. PubMed ID: 27417445
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
    Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of pyruvate dehydrogenase is an independent prognostic marker in gastric cancer.
    Sun XR; Sun Z; Zhu Z; Guan HX; Li CY; Zhang JY; Zhang YN; Zhou H; Zhang HJ; Xu HM; Sun MJ
    World J Gastroenterol; 2015 May; 21(17):5336-44. PubMed ID: 25954108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.
    Meyerhardt JA; Niedzwiecki D; Hollis D; Saltz LB; Hu FB; Mayer RJ; Nelson H; Whittom R; Hantel A; Thomas J; Fuchs CS
    JAMA; 2007 Aug; 298(7):754-64. PubMed ID: 17699009
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum protein profiling using an aptamer array predicts clinical outcomes of stage IIA colon cancer: A leave-one-out crossvalidation.
    Huh JW; Kim SC; Sohn I; Jung SH; Kim HC
    Oncotarget; 2016 Mar; 7(13):16338-48. PubMed ID: 26908450
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer.
    Cakar B; Varol U; Junushova B; Muslu U; Gursoy Oner P; Gokhan Surmeli Z; Cirak Y; Karaca B; Sezgin C; Karabulut B; Uslu R
    J BUON; 2013; 18(2):372-6. PubMed ID: 23818348
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and Prognostic Implications of Transcription Factor SOX4 in Patients with Colon Cancer.
    Lin CM; Fang CL; Hseu YC; Chen CL; Wang JW; Hsu SL; Tu MD; Hung ST; Tai C; Uen YH; Lin KY
    PLoS One; 2013; 8(6):e67128. PubMed ID: 23826209
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
    Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
    Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical significance of microRNA-93 downregulation in human colon cancer.
    Xiao ZG; Deng ZS; Zhang YD; Zhang Y; Huang ZC
    Eur J Gastroenterol Hepatol; 2013 Mar; 25(3):296-301. PubMed ID: 23354160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low CA II expression is associated with tumor aggressiveness and poor prognosis in gastric cancer patients.
    Hu X; Huang Z; Liao Z; He C; Fang X
    Int J Clin Exp Pathol; 2014; 7(10):6716-24. PubMed ID: 25400751
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic factors for survival after curative resection of Dukes' B colonic cancer.
    Saha AK; Smith KJ; Sue-Ling H; Sagar PM; Burke D; Finan PJ
    Colorectal Dis; 2011 Dec; 13(12):1390-4. PubMed ID: 21073647
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Implication of Serine Metabolism-Associated Enzymes in Colon Cancer.
    Yoon S; Kim JG; Seo AN; Park SY; Kim HJ; Park JS; Choi GS; Jeong JY; Jun do Y; Yoon GS; Kang BW
    Oncology; 2015; 89(6):351-9. PubMed ID: 26439504
    [TBL] [Abstract][Full Text] [Related]  

  • 58. p66 Shc tumor levels show a strong prognostic correlation with disease outcome in stage IIA colon cancer.
    Grossman SR; Lyle S; Resnick MB; Sabo E; Lis RT; Rosinha E; Liu Q; Hsieh CC; Bhat G; Frackelton AR; Hafer LJ
    Clin Cancer Res; 2007 Oct; 13(19):5798-804. PubMed ID: 17908971
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of pim-1 in tumors, tumor stroma and tumor-adjacent mucosa co-determines the prognosis of colon cancer patients.
    Peng YH; Li JJ; Xie FW; Chen JF; Yu YH; Ouyang XN; Liang HJ
    PLoS One; 2013; 8(10):e76693. PubMed ID: 24116137
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage I-III colon cancer.
    Zhou R; Zeng D; Zhang J; Sun H; Wu J; Li N; Liang L; Shi M; Bin J; Liao Y; Huang N; Liao W
    EBioMedicine; 2019 Apr; 42():420-430. PubMed ID: 30917936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.